The patent covers the technology in combination with Carbidopa and Levodopa (AP-CD/LD) – currently in a Phase III trial for advanced Parkinson’s disease – until April 2029.
The Accordion Pill fits inside a standard size capsule, and is composed of a multi-layer, planar structure, reminiscent of an accordion.
According to Intec, when the capsule reaches the stomach, the capsule unfolds, and the accordion structure made of pharmaceutical biodegradable polymeric films, dissolves.
The structure remains in the stomach for up to 12 hours said the firm, allowing it to release the drug into the upper gastrointestinal tract in a controlled manner.
“Retaining the dosage form in the stomach and releasing the drug in a controlled manner enable prolonged and continuous absorption phase of the drug in the upper part of the gastrointestinal tract, resulting in improved efficacy and safety profile, as well as reduced frequent daily dosing,” said the firm.
The pill is suitable for drugs that are poorly soluble. It can be used to combine immediate and controlled-release drugs, and deliver more than one active pharmaceutical ingredient (API) at the same time.
The firm said it plans to increase its patent portfolio, which includes the US, Europe, China, Japan, South Korea, Hong Kong, South Africa, and Israel.
Intec is also developing an Accordion Pill combination treatment using cannabidiol and tetrahydrocannabinol (AP-CBD/THC) for indications including low back neuropathic pain and fibromyalgia.
The Israel-headquartered firm said AP-CBD/THC could help address drawbacks in current methods of use with cannabis and cannabinoids, such as short duration of effect and delayed onset.